Richard Peck
Fondatore presso Cellestia Biotech AG
Posizioni attive di Richard Peck
Società | Posizione | Inizio | Fine |
---|---|---|---|
Cellestia Biotech AG
Cellestia Biotech AG Pharmaceuticals: MajorHealth Technology Cellestia Biotech AG manufactures anti-cancer drugs. Its pipeline product includes CB-103, a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma, and solid tumors. The firm holds a worldwide exclusive license on the intellectual property rights for the development and commercialization of CB-103 and related series of close analogues. The company was founded by Freddy Radtke, Michael Bauer, Richard Peck, Dirk Weber and Rajwinder Lehal in 2014 and is headquartered in Basel, Switzerland. | Fondatore | 01/01/2014 | - |
Consigliere Generale | 01/01/2014 | - |
Storia della carriera di Richard Peck
Precedenti posizioni note di Richard Peck
Società | Posizione | Inizio | Fine |
---|---|---|---|
Finox Biotech AG
Finox Biotech AG Medical/Nursing ServicesHealth Services Finox AG specializes in developing fertility drugs. Its products include BEMFOLA, a recombinant-human follicle-stimulating hormone. The company was founded by Michel Wilhelm in 2007 and is headquartered in Burgdorf, Switzerland. | Consigliere Generale | 01/01/2010 | - |
Statistiche
Distribuzione geografica
Svizzera | 3 |
Posizioni
General Counsel | 2 |
Founder | 1 |
Settori
Health Services | 2 |
Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 2 |
---|---|
Finox Biotech AG
Finox Biotech AG Medical/Nursing ServicesHealth Services Finox AG specializes in developing fertility drugs. Its products include BEMFOLA, a recombinant-human follicle-stimulating hormone. The company was founded by Michel Wilhelm in 2007 and is headquartered in Burgdorf, Switzerland. | Health Services |
Cellestia Biotech AG
Cellestia Biotech AG Pharmaceuticals: MajorHealth Technology Cellestia Biotech AG manufactures anti-cancer drugs. Its pipeline product includes CB-103, a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma, and solid tumors. The firm holds a worldwide exclusive license on the intellectual property rights for the development and commercialization of CB-103 and related series of close analogues. The company was founded by Freddy Radtke, Michael Bauer, Richard Peck, Dirk Weber and Rajwinder Lehal in 2014 and is headquartered in Basel, Switzerland. | Health Technology |
- Borsa valori
- Insiders
- Richard Peck
- Esperienza